Hospital admissions · patients with acute asthma
IV + inhaled beta agonist showed no clear difference in admissions to hospital compared with inhaled beta‐agonist (low certainty).
1 finding from 1 review
Healthcare use: length of stay in the emergency department · patients with acute asthma
IV + inhaled beta agonist showed no clear difference in length of stay in emergency department compared with inhaled beta‐agonist (moderate certainty).
1 finding from 1 review
Pulse rate at 2 hours · patients with acute asthma
IV + inhaled beta agonist showed no clear difference in pulse rate at 2 hours compared with inhaled beta‐agonist (moderate certainty).
1 finding from 1 review
Clinical Failure (children with a severe to moderate overall clinical assessment score at two hours) · patients with acute asthma
IV + inhaled beta agonist probably leads to lower clinical Failure (children with a severe to moderate overall… compared with inhaled beta‐agonist (moderate certainty).
1 finding from 1 review
Annual Exacerbation Rates · people with bronchiectasis
Inhaled mannitol showed no clear difference in exacerbations Exacerbation rate per year. compared with placebo (moderate certainty).
1 finding from 1 review
Hospitalisations Number of participants experiencing one of more hospitalisations. · people with bronchiectasis
Inhaled mannitol showed no clear difference in hospitalisations Number of participants experiencing one of more… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with bronchiectasis
Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis
Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).
1 finding from 1 review
Symptoms Bronchiectasis Symptoms Questionnaire · people with bronchiectasis
Inhaled mannitol showed no clear difference in symptoms Bronchiectasis Symptoms Questionnaire compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 (L) · people with bronchiectasis
Inhaled mannitol showed no clear difference in lung function FEV1 (L) compared with placebo (moderate certainty).
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · people with bronchiectasis
1 finding from 1 review
Number of participants improved · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in number of participants improved compared with placebo (low certainty).
1 finding from 1 review
Lung function (spirometry indices) ‐ FVC (in L, end study minus baseline values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ diffusion capacity % predicted (end of study) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ RV % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Lung function (other indices) ‐ TLC % predicted (end of study values) · people with bronchiectasis
1 finding from 1 review
Exacerbations · people with bronchiectasis
1 finding from 1 review
Pseudomonas aeruginosa (P aeruginosa) colonisation · people with bronchiectasis
Inhaled corticosteroids showed no clear difference in pseudomonas aeruginosa (P aeruginosa) colonisation compared with placebo (low certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · people with bronchiectasis
1 finding from 1 review